nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

07.01.2021 | Inflammatory Disorders

Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis

verfasst von: Ryuto Nishisho, Sentaro Kusuhara, Noriyuki Sotani, Kyong Woo Kim, Atsuko Katsuyama-Yoshikawa, Wataru Matsumiya, Kengo Akashi, Akio Morinobu, Makoto Nakamura

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the short-term change in choroidal structure following adalimumab (ADA) treatment in refractory noninfectious uveitis.

Methods

This was a retrospective study of 33 eyes from 18 patients with refractory noninfectious uveitis. Subfoveal choroidal thickness (SFCT), the choroidal stromal index (CSI) defined as the proportion of stromal area to the total choroidal area were used as choroidal imaging parameters and were evaluated by enhanced depth imaging optical coherence tomography (EDI-OCT). The change in these parameters in the 2 months following initiation of ADA was analysed. A linear mixed-effect model was used to assess the effect of ADA treatment.

Results

The causes of uveitis were Vogt-Koyanagi-Harada disease (VKHD) (42.4%), presumed autoimmune retinopathy (15.2%), others (12.1%) and unclassified (30.3%). In the analysis of all eyes, the SFCT was 309.7 ± 113.1 μm at baseline, 295.7 ± 114.5 μm at 1 month and 275.2 ± 98.8 μm at 2 months after ADA initiation (P < 0.001). The CSI was 0.275 ± 0.050 at baseline, 0.273 ± 0.068 at 1 month and 0.273 ± 0.046 at 2 months (P = 0.785). In the subgroup analysis, the SFCT decreased significantly from baseline to 2 months in VKHD eyes (P = 0.007) and unclassified eyes (P = 0.034). There was no significant change in CSI in either subgroup.

Conclusions

In the assessment of short-term response to ADA treatment in uveitic eyes, using EDI-OCT, the SFCT appears to be more effective as a choroidal imaging biomarker than the CSI, especially in VKHD eyes.

Nur mit Berechtigung zugänglich

Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932–943. https://doi.org/10.1056/NEJMoa1509852CrossRefPubMed

Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192. https://doi.org/10.1016/s0140-6736(16)31339-3CrossRefPubMed

Suhler EB, Adan A, Brezin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD (2018) Safety and efficacy of Adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125(7):1075–1087. https://doi.org/10.1016/j.ophtha.2017.12.039CrossRefPubMed

Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516. https://doi.org/10.1016/j.ajo.2005.03.057CrossRefPubMed

Deak GG, Zhou M, Sporysheva A, Goldstein DA (2020) Novel imaging modalities in patients with uveitis. Can J Ophthalmol 55(1):20–29. https://doi.org/10.1016/j.jcjo.2019.06.005CrossRefPubMed

Nickla DL, Wallman J (2010) The multifunctional choroid. Prog Retin Eye Res 29(2):144–168. https://doi.org/10.1016/j.preteyeres.2009.12.002CrossRefPubMed

Pichi F, Invernizzi A, Tucker WR, Munk MR (2020) Optical coherence tomography diagnostic signs in posterior uveitis. Prog Retin Eye Res 75:100797. https://doi.org/10.1016/j.preteyeres.2019.100797CrossRefPubMed

Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146(4):496–500. https://doi.org/10.1016/j.ajo.2008.05.032CrossRefPubMed

Staurenghi G, Sadda S, Chakravarthy U, Spaide RF, International Nomenclature for Optical Coherence Tomography Panel (2014) Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN*OCT consensus. Ophthalmology 121(8):1572–1578. https://doi.org/10.1016/j.ophtha.2014.02.023CrossRefPubMed

10.

Nakai K, Gomi F, Ikuno Y, Yasuno Y, Nouchi T, Ohguro N, Nishida K (2012) Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 250(7):1089–1095. https://doi.org/10.1007/s00417-011-1910-7CrossRefPubMed

11.

Goldenberg D, Goldstein M, Loewenstein A, Habot-Wilner Z (2013) Vitreal, retinal, and choroidal findings in active and scarred toxoplasmosis lesions: a prospective study by spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 251(8):2037–2045. https://doi.org/10.1007/s00417-013-2334-3CrossRefPubMed

12.

Invernizzi A, Mapelli C, Viola F, Cigada M, Cimino L, Ratiglia R, Staurenghi G, Gupta A (2015) Choroidal granulomas visualized by enhanced depth imaging optical coherence tomography. Retina 35(3):525–531. https://doi.org/10.1097/IAE.0000000000000312CrossRefPubMed

13.

Agrawal R, Salman M, Tan KA, Karampelas M, Sim DA, Keane PA, Pavesio C (2016) Choroidal vascularity index (CVI)--a novel optical coherence tomography parameter for monitoring patients with Panuveitis? PLoS One 11(1):e0146344. https://doi.org/10.1371/journal.pone.0146344CrossRefPubMedPubMedCentral

14.

Egawa M, Mitamura Y, Akaiwa K, Semba K, Kinoshita T, Uchino E, Sonoda S, Sakamoto T (2016) Changes of choroidal structure after corticosteroid treatment in eyes with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 100(12):1646–1650. https://doi.org/10.1136/bjophthalmol-2015-307734CrossRefPubMed

15.

Kawano H, Sonoda S, Yamashita T, Maruko I, Iida T, Sakamoto T (2016) Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment. Graefes Arch Clin Exp Ophthalmol 254(3):421–426. https://doi.org/10.1007/s00417-016-3283-4CrossRefPubMed

16.

Tagawa Y, Namba K, Mizuuchi K, Takemoto Y, Iwata D, Uno T, Fukuhara T, Hirooka K, Kitaichi N, Ohno S, Ishida S (2016) Choroidal thickening prior to anterior recurrence in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 100(4):473–477. https://doi.org/10.1136/bjophthalmol-2014-306439CrossRefPubMed

17.

Skvortsova N, Gasc A, Jeannin B, Herbort CP (2017) Evolution of choroidal thickness over time and effect of early and sustained therapy in birdshot retinochoroiditis. Eye (Lond) 31(8):1205–1211. https://doi.org/10.1038/eye.2017.54CrossRef

18.

No authors listed (1990) Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease 367. Lancet 335(8697):1078–1080

19.

Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652. https://doi.org/10.1016/s0002-9394(01)00925-4CrossRefPubMed

20.

Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M (2012) The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol 56(5):432–435. https://doi.org/10.1007/s10384-012-0158-zCrossRefPubMed

21.

Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA, International Workshop on Ocular Sarcoidosis Study Group (2019) Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol 103(10):1418–1422. https://doi.org/10.1136/bjophthalmol-2018-313356CrossRefPubMed

22.

Fox AR, Gordon LK, Heckenlively JR, Davis JL, Goldstein DA, Lowder CY, Nussenblatt RB, Butler NJ, Dalal M, Jayasundera T, Smith WM, Lee RW, Adamus G, Chan CC, Hooks JJ, Morgans CW, Detrick B, Sen HN (2016) Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach. Am J Ophthalmol 168:183–190. https://doi.org/10.1016/j.ajo.2016.05.013CrossRefPubMedPubMedCentral

23.

Sonoda S, Sakamoto T, Yamashita T, Uchino E, Kawano H, Yoshihara N, Terasaki H, Shirasawa M, Tomita M, Ishibashi T (2015) Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am J Ophthalmol 159(6):1123–1131 e1121. https://doi.org/10.1016/j.ajo.2015.03.005CrossRefPubMed

24.

Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92(4):467–471. https://doi.org/10.1016/s0161-6420(85)34001-0CrossRefPubMed

25.

Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, Androudi S (2018) A focus on the epidemiology of uveitis. Ocul Immunol Inflamm 26(1):2–16. https://doi.org/10.1080/09273948.2016.1196713CrossRefPubMed

26.

Al-Janabi A, El Nokrashy A, Sharief L, Nagendran V, Lightman S, Tomkins-Netzer O (2020) Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or Panuveitis. Ophthalmology 127(3):410–416. https://doi.org/10.1016/j.ophtha.2019.08.031CrossRefPubMed

27.

Singh SR, Vupparaboina KK, Goud A, Dansingani KK, Chhablani J (2019) Choroidal imaging biomarkers. Surv Ophthalmol 64(3):312–333. https://doi.org/10.1016/j.survophthal.2018.11.002CrossRefPubMed

28.

Pirani V, Pelliccioni P, De Turris S, Rosati A, Franceschi A, Pasanisi P, Gesuita R, Nicolai M, Mariotti C (2020) Intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy. J Clin Med 9(2). https://doi.org/10.3390/jcm9020510

29.

Maruko I, Iida T, Sugano Y, Oyamada H, Sekiryu T, Fujiwara T, Spaide RF (2011) Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina 31(3):510–517. https://doi.org/10.1097/IAE.0b013e3181eef053CrossRefPubMed

30.

Nakayama M, Keino H, Okada AA, Watanabe T, Taki W, Inoue M, Hirakata A (2012) Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease. Retina 32(10):2061–2069. https://doi.org/10.1097/IAE.0b013e318256205aCrossRefPubMed

31.

da Silva FT, Sakata VM, Nakashima A, Hirata CE, Olivalves E, Takahashi WY, Costa RA, Yamamoto JH (2013) Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease. Br J Ophthalmol 97(1):70–74. https://doi.org/10.1136/bjophthalmol-2012-302089CrossRefPubMed

32.

Agrawal R, Li LK, Nakhate V, Khandelwal N, Mahendradas P (2016) Choroidal vascularity index in Vogt-Koyanagi-Harada disease: an EDI-OCT derived tool for monitoring disease progression. Transl Vis Sci Technol 5(4):7. https://doi.org/10.1167/tvst.5.4.7CrossRefPubMedPubMedCentral

Titel: Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis
verfasst von: Ryuto Nishisho
Sentaro Kusuhara
Noriyuki Sotani
Kyong Woo Kim
Atsuko Katsuyama-Yoshikawa
Wataru Matsumiya
Kengo Akashi
Akio Morinobu
Makoto Nakamura
Publikationsdatum: 07.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 5/2021
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-05032-9

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration

Big data simulations for capacity improvement in a general ophthalmology clinic

Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia

Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up

Optical coherence tomography angiography findings in patients undergoing transcorneal electrical stimulation for treating retinitis pigmentosa

Prediction of probability of rubella based on eye outcomes (PORBEO Nomogram)—a cross-sectional sentinel surveillance of 1134 infants

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde